The government “can’t find” $20 trillion, while pension funds are tanking

The government “can’t find” $20 trillion, while pension funds are tanking

Note: the missing $20 trillion does not refer to the national debt.

by Jon Rappoport

April 24, 2018

Alert to pension fund managers all over the planet—and to everyone else—

“If 1,000 US and global pension fund managers start asking questions it could change everything – like stopping a nuclear war.”

That’s a statement from former US Assistant Secretary of Housing and Urban Development, and now president of Solari, Inc., Catherine Austin Fitts, who is a financial analyst like no other in our time.

Among other feats, she has identified a giant sucking black hole in the US government. And what has disappeared down that hole is money. Over the years, at least $20 trillion.

Unaccounted for.

Gone.

If you’re a pension fund manager, stop reading this article and immediately switch over to Fitts’ article, “The State of Our Pension Funds.”

You could begin to see a blinding light that changes your mind and changes your approach to the staggering debt your fund is dealing with. And in the process, you could help lead the way to a peaceful revolution. A far-reaching revolution, in which wide-ranging prosperity, not doom, sits up the road.

As for everyone else, here are a few of Fitts’ quotes from her mind-repairing article:

“So what is the problem? If it’s not a problem for $21 trillion to go missing from DOD and HUD, and, [if] it’s possible [for the government] to come up with more than $20[plus] trillion to give or loan to the banks [in a bailout] — when there is no legal obligation to do so, and, when we [the government] can transfer trillions of the most valuable technology in the world to private corporations at zero cost to them and [at] great cost to the taxpayers, [then] I assure you that fixing whatever pension fund problem there is, is not difficult. However, the political will must exist and want to. That is the problem.”

“If we can print money to give $20 trillion [plus] to the banks, and, [if we can] let $21 trillion go missing from the federal government, [then] why is it a problem to print $5 trillion to fund the pension funds?”

Failing pension funds are on the hook for $5 trillion, and the federal government has no answer? Well, that is a supreme con job, because, as Fitts points out, the government is playing far larger money games without a shred of concern.

And this is just the beginning of the rabbit hole Fitts has been traveling for the past several decades. Here is her basic position: Prosperity for the many, not the few, is eminently possible and doable.

Starting from that premise, and deploying her relentless skills as an analyst, she has discovered the strategies the government and mega-corporations have been deploying to undermine and torpedo an economically healthy society.

Finding and illuminating these strategies was not her basic intent. Her basic intent was lifting all boats for the citizenry. In pursuing that course, she came upon the secret obstructions.

And because her desire to help people did not waver in the slightest, she didn’t turn away. She exposed the obstructions. She continues to do so.

She writes: “Family wealth has the distinct advantage of returning control of investment decisions to individuals. However, this is hardly what the US establishment wants.”

“Our planetary governance and financial system currently operates significantly outside of the law. Whether the cost of war, organized crime, corruption, environmental damage, suppression of technology or secrecy, this lawlessness – and the lawlessness it encourages in the general population – represents a heavy and expensive drag on all aspects of our society, our economy and our landscape.”

Fitts cites an example of corporate choices in this lunatic money scam—General Electric: “By some estimates, its pension fund is underfunded to the tune of $31 billion. However, during the time its pension fund became so underfunded, GE spent $45 billion to buy back its publicly traded common stock. The needed funds were there at one point; it’s just that the leadership of the company decided to funnel it into stockholders’ hands rather than to the pensions of the employees who helped build the company.”

Do you have a pension fund manager? Do you know a pension fund manager? Link them to Fitts’ article. It’s long past the time when they can sit back and moan about the trouble they’re in. They need to learn about the underlying forces at work. (And if they’re a conscious part of the problem, let them learn that their game is exposed.)

Look around you. Money is everywhere. Titanic piles of it are flowing. The question is, to whom is it flowing, and how, and why? Within the current system, there are designated winners and losers. This has to do with criminal controllers posing as benefactors. They steer the money ship. They dump shipments of money at certain favored ports and keep shipments from reaching many other ports.

I know there are people out there who will say, “It’s all about the illegal Federal Reserve and the transnational bankers.” That’s like saying the drug problem is all about the Mexican cartels—but then, digging further, you also come across the expanding opium poppy fields in Afghanistan, the hands-off collusion in Chicago that permits the city to act as a primary hub for drug distribution in the US, the pharmaceutical companies that traffic millions of opioid pills to dealers, and the 2016 law that strangled DEA efforts to bust those companies.

The devil is in the details, and Fitts has uncovered an astonishing number of them.

I first came across her work about ten years ago, when we spoke several times about her specific method enabling local communities to discover money flows—the sources of money coming into their towns and cities, and the destinations of money going out. This brilliant tool would give communities the power to see exactly how money was impoverishing them, rather than enriching them. In an effort to make that tool widely available, thus pointing the way for communities to change those flows and foster local prosperity, Fitts ran into legal trouble with the federal government—and “trouble” is a vast understatement.

She emerged, after a long battle, with her primary goals securely intact.

She has answers and solutions.

Answers that are vital for our time.

Fitts was once an insider and had a front row seat at the money circus. Now, her ongoing enterprise is solari.com. I highly recommend it to you.


The Matrix Revealed

(To read about Jon’s mega-collection, The Matrix Revealed, click here.)


Huge drug (pharma) money changes hands in high-level financial deals—why?

Huge drug (pharma) money changes hands in high-level financial deals—why?

by Jon Rappoport

April 19, 2018

These are notes on money-musical-chairs among drug companies. Big-time money.

Clues as to why there is such a tidal wave of cash:

One: Consolidation, of course. Fewer giant companies, who have greater control over the market, are too big to fail, and have more lobbying power with governments.

Two: The companies are making deals left and right to temporarily give stockholders and prospective investors the impression that “something good” is happening, while concealing the fact that numerous new drugs in the testing pipeline are failing to produce beneficial results, and are unsafe. Sleight of hand.

Three: The companies are making very favorable loan deals with banks, enabling them to buy out other drug firms. Before the loan repayments are completed, the companies will have sold themselves (and the debt) to bigger fish.

Four: A drug company knows its development of a new drug is fraudulent, and is riddled with illegal practices, such as lack of informed consent in recruiting volunteers for clinical trials. So it sells the research unit for that drug to another company, making it their problem.

Here are $$ details. Follow the astonishing money trails.

From: https://www.fiercepharma.com/m-a/sanofi-advent-international-nearing-eu2b-deal-for-european-generics-business-report:

“Other bidders may have dropped out of an auction for Sanofi’s European generics unit, but that doesn’t mean it hasn’t found a buyer. The drugmaker is nearing an agreement and could announce a sale in the next several days, Bloomberg reports.

“Sanofi’s board could meet as soon as Monday to vote on a deal worth about €2 billion ($2.48 billion), according to the news service’s sources. Of course, the sources note that the deal isn’t final and that it could ultimately fail to materialize.

“The news follows previous decisions by private equity firm Nordic Capital and Indian drugmaker Torrent Pharma to bow out of negotiations, worried that the unit is too pricey, according to press reports. PE firm Carlyle Group and Brazil’s EMS remained in deal talks through final bidding, according to Bloomberg.

“And that’s not the only deal Sanofi has had in the works. The company has been toiling to reshape itself for several years, and as part of that effort on Monday sold 12 “noncore” pharma brands to Cooper-Vemedia for €158 million, a spokesperson confirmed.

“The drugmaker talked about selling the business in 2015, but CEO Olivier Brandicourt made other M&A moves after coming on board instead. In 2016, Brandicourt offloaded Sanofi’s animal health unit Merial in an asset swap with Boehringer Ingelheim, getting BI’s consumer health business in return.

“The drugmaker hasn’t only slimmed down, though. Sanofi purchased nanobody biotech Ablynx for $4.8 billion and hemophilia-focused Bioverativ for $11.6 billion in sizable deals early this year. Afterward, Brandicourt said the acquisitions “dramatically reshape our portfolio in specialty care” and boost the company’s R&D presence.”

Here is more: https://www.fiercepharma.com/pharma/takeda-still-eyeing-a-buy-shire-casts-off-oncology-for-2-4b:

“With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.

“On Monday, Shire announced it had agreed to hand its oncology business to France’s Servier for $2.4 billion, a move it said would sharpen its focus on rare diseases. And more streamlining deals are likely on the way.

“While the oncology business has delivered high growth and profitability, we have concluded that it is not core to Shire’s longer-term strategy,” CEO Flemming Ornskov said in a statement, adding that “we will continue to evaluate our portfolio for opportunities to unlock further value … with selective disposals of nonstrategic assets.”

“Meanwhile, Servier will land an “immediate presence” in the U.S. with products such as Oncaspar, which Shire nabbed in its Baxalta buyout. Baxter had bought the med to diversify its pharmaceutical portfolio before spinning it off into Baxalta, which Shire later picked up after a monthslong pursuit.

“The oncology move makes things interesting for Japanese drugmaker Takeda, which late last month made its buyout interest in Shire public.

“The deal should … boost Shire’s negotiating position on asking price in the current offer period with Takeda, in our view,” Jefferies analyst Peter Welford wrote in a note to clients.”

And more: https://www.fiercepharma.com/pharma/mylan-s-advanced-talks-for-merck-kgaa-s-4b-plus-otc-unit-report:

“Pfizer may have run into snags trying to sell its consumer health business, but Merck KGaA may be in advanced discussions with a player over its own for-sale unit. And that player is Mylan, according to reports.

“The two companies are negotiating a price between $4.3 billion and $4.9 billion, Reuters says, although there’s no certainty they’ll lock down a deal. The German drugmaker has also reportedly chit-chatted with private equity groups about a sale, according to the news service.

“Mylan, for its part, denies the report. “Although it’s Mylan’s policy to not comment on rumors or speculation, given the egregious inaccuracy of reports issued this morning, the company is compelled to confirm that the Reuters article is untrue,” the company said in a statement.

“It’s not the first time Mylan has gone after a deal in the consumer biz. It spent the better part of 2015 in hostile pursuit of store-brand specialist Perrigo, whose shareholders ultimately rejected Mylan’s offer. And in the wake of that offer, it snapped up Sweden’s Meda.

“It’s also not the first time Mylan and Merck KGaA have talked transaction, Reuters noted. Back in 2007, Mylan took Merck’s generics unit off its hands in a $6.7 billion deal that also sent severe allergy blockbuster EpiPen over to the copycat.

“Meanwhile, Pfizer, which boasts a larger OTC business than Merck’s, has been watching its own sale options dwindle as retail kings such as Amazon threaten OTC drugmakers’ sales. Late last month, both Reckitt and GlaxoSmithKline withdrew from the bidding process, though rumor has it there’s a small chance the New York drugmaker could still unload the asset to Procter & Gamble.”

And now, here is a list of top pharma mergers and acquisitions in the past several years:

10. Abbott-Alere, $5.8bn, 2016
“At the start of February American pharmaceutical giant Abbot agreed to buy Alere Inc. for $5.8bn or $56 a share to become the lead holder in the market for medical tests and diagnostics. Alere which has annual sales of about $2.5bn makes tests for infections such as malaria, HIV, dengue fever and tuberculosis. Abbott stated that at the end of 2015 its diagnostic sales were $4.6bn, a figure which would now exceed the $7bn-a-year mark. Abbott currently has more than 73,000 employees and revenues in 2015 reached $20.405bn.”

9. Mylan-Meda, $7.2bn, 2016
“February, 2016 saw Mylan agree a takeover of Swedish drug maker Meda for $7.2bn. The new company is expected to have 2015 sales of $11.8bn, and the deal also boosts Mylan’s range of branded and generic medications and gives it an additional leg-up in the area of over-the-counter medications that will now achieve sales of around $1bn a year. Mylan had been in pursuit of Meda for a while before the deal closed, having two offers rejected in 2014 that were valued at $6.7bn. Mylan is a global generic and specialty pharmaceutical company registered in the Netherlands with headquarters in the UK. It currently provides more than 30,000 pharmaceutical jobs.”

8. Celgene-Receptos, $7.2bn, 2015
“In August, 2015, American biotechnology company Celgene acquired Receptos for $7.2bn and its phase III autoimmune treatment for ulcerative colitis and multiple sclerosis. If all goes to plan the drug could end up bringing in peak sales as high as $6bn. Celgene was founded in 1986 and currently has more than 4,100 employees. In 2015 the company achieved a 21% year-on-year growth in product sales reaching $9.2bn.”

7. Endo International-Par Pharmaceutical, $8.1bn, 2015
“Endo International, headquartered in Ireland and the USA, is a global specialty pharmaceutical company employing more than 6,200 people. In September last year, it completed its buyout of Par Pharmaceutical in a deal worth $8.1bn. The acquisition firmly establishes Endo as one of the world’s fastest growing and notable generics businesses and will help the company to position itself for strong growth in the years to come.”

6.Alexion Pharmaceuticals-Synageva BioPharma, $8.4bn, 2015
“In June, 2015 Connecticut-based Alexion Pharmaceuticals successfully completed its acquisition of Synageva BioPharma for $8.4bn. The acquisition strengthened Alexion’s global leadership in devastating and rare diseases, and created one of the strongest rare disease portfolios in the biotech industry. Alexion was founded in 1992 and employs more than 3,000 people serving 50 countries worldwide.”

5. Valeant-Salix Pharmaceuticals, $15.8bn, 2015
“March, 2015, saw Canadian-based Valeant acquire Salix Pharmaceuticals for $15.8bn, adding to its portfolio of gastroenterology drugs. The $158-per-share deal came after reports that Valeant had been competing with Shire for a takeover of Salix. In addition to the $15.8bn price tag, Valeant would absorb $5bn in debt and the merger would provide $500m a year in cost-saving opportunities and cut the tax paid on Salix revenues which stood at 35%. Valeant currently employs around 17,000 individuals and achieved revenues of $10.5bn in 2015.”

4. Pfizer-Hospira, $17bn, 2015
“US-based pharmaceutical giant Pfizer agreed to buy Hospira in a $17bn takeover that would expand its portfolio of drugs and add Hospira’s portfolio of sterile injectable treatments and biosimilar drugs to Pfizer’s broad offerings. At the time Hospira had 11 biosimilar molecules in its pipeline, with the market value for biosimilars and sterile injectables set to reach around $90bn by 2020. The deal was expected to provide around $800m a year in cost-savings by 2018. Pfizer achieved revenues of $49bn last year and currently provides more than 78,000 pharmaceutical jobs.”

3. AbbVie-Pharmacyclics, $21bn, 2015
“In May, 2015, AbbVie closed a deal to buy California-based Pharmacyclics for $21bn. The massive deal would boost AbbVie’s cancer portfolio substantially. AbbVie currently relies heavily on its ageing $10bn-a-year auto inflammatory drug Humira, and 2 years earlier split from its partner Abbott in the hopes of finding large merger deals to fill its sparse drugs pipeline. One of the driving factors for the merger was Pharmacyclics blood cancer drug, Imbruvica, which is expected to achieve worldwide sales of $5.8bn by 2020. AbbVie achieved revenues of $22bn in 2015 and currently employs more than 28,000 people.”

2.Shire-Baxalta, $32bn, 2016
“In January 2016 Shire finally closed a deal to acquire Baxalta for $32bn after 6 months of negotiations. Shire stated that the new firm would be able to achieve double-digit sales growth to over $20bn by 2020, with about two-thirds of this revenue coming from immunology, neuroscience, haematology, lysosomal storage disorders, gastrointestinal diseases and heredity angioedema. Both companies are predicting around $500m in annual cost-savings within the first 3 years, with the combined tax rate down 7% to 16%.”

1.Teva-Allergan Generics, $40.5bn, 2015
“July, 2015, saw Israeli firm Teva buy Allergan’s generics unit for a massive $40.5bn in cash and stock. The deal meant that Allergan received $33.75bn in cash and Teva shares valued at $6.75bn, giving it a 10% stake in Teva. Investors had been pressuring Teva to make a major deal as generics erosion meant that the firm could face severe losses from its $4.2bn a year multiple sclerosis drug Copaxone. Teva hopes that the deal with Allergan generics will establish a foundation for long-term sustainable growth and assist in building a strong portfolio of products in both generics and specialty areas. Teva achieved revenues of around $20bn in 2014, and currently employs more than 40,000 individuals.”


The Matrix Revealed

(To read about Jon’s mega-collection, The Matrix Revealed, click here.)


Jon Rappoport

The author of three explosive collections, THE MATRIX REVEALED, EXIT FROM THE MATRIX, and POWER OUTSIDE THE MATRIX, Jon was a candidate for a US Congressional seat in the 29th District of California. He maintains a consulting practice for private clients, the purpose of which is the expansion of personal creative power. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world. You can sign up for his free NoMoreFakeNews emails here or his free OutsideTheRealityMachine emails here.

Globalists weaponize the stock market to control presidents

Globalists weaponize the stock market to control presidents

Anatomy of a fake reality

by Jon Rappoport

March 4, 2018

The economy is on the rise. No, it’s sinking. There are very good indicators. No, all the signals are catastrophic.

We’ve seen pundits on television hawking their version of the near future. Many of them represent organizations who have political and financial agendas.

For example, Globalist forces and their mouthpieces would have you believe that laying tariffs on imports will sink the stock market.

However, since the stock market is a rigged game for insiders, here is a proper translation of the above paragraph: “If tariffs are laid on, Globalist insiders will MAKE the stock market sink, and characterize that as a natural consequence of the new tariffs.”

In turn, then, a diving stock market will be PROMOTED (by the Globalist press) as a sign that the overall economy is in big trouble.

Trump surrounded himself with Goldman Sachs people because they could give him a rising stock market.

This is not an ironclad agreement. If Goldman decides Trump’s policies are wandering off-track, they can bail on him and send the stock market down.

This is how the economic game is played.

The return of some corporations from overseas, to set up factories in the US again? Fine. No problem. But Trump’s statement, several days ago, that he would lay a 25% tariff on imported steel and a 10% tariff on aluminum—that’s an anti-Globalist earthquake.

Globalist leaders in foreign countries are lining up to say they’ll retaliate. They’ll lay tariffs on imports from America. Bourbon, jeans, motorcycles, orange juice, rice. But is this the end of the world? No. It should be the first step in sorting out unfair and ruinous trade policies that have eaten into the US economy for decades.

The stock market is hyped as the prime indicator that passes judgment on what Trump (or any president) is doing. If it falls precipitously, that means he’s wrong and very badly wrong.

But in truth, the stock market is a separate giant Vegas casino. Investment funds’ algorithms move billions in and out of trades, minute by minute. Individual speculators bet on rises and falls. Claiming the condition of the entire US economy is reflected in the stock market is like saying the Powerball lottery reveals the financial health or sickness of the US automobile industry.

The stock market and the precious Dow are set up as a very profitable playground for insiders. That’s the beginning and the end of that story.

Imagine we have a company, X, which is listed on the New York Stock Exchange. Its price is very low, and has been low for quite some time. It crawls along, doing nothing.

Quietly, insiders are buying up the stock. When they’re ready, they take the price up. Then the rubes, seeing the rise, buy the stock, too. THEN there is a shakeout: the insiders momentarily take the stock price down. The rubes, frightened, sell—and the insiders scoop up those shares. Now they’re really ready. They take the stock for a long ride. Up. They make a bundle. When they’ve had enough, they put out news that company X’s stock is a terrific buy. The rubes buy in—but this the top. The insiders unload their shares on the rubes and take stock price down. The insiders also sell short (bet against a rise) and profit on the way down. It’s a piece a cake, a very handsome piece of cake.

This is the game. It really has nothing at all to do with the condition of the economy.

But—there is another game. The insiders, through their minions in the press, continue to promote the illusion that the overall condition of the stock market reveals “how the economy is doing.”

Therefore, by being able to control the stock market, the insiders can control THE PERCEPTION of how the economy is doing.

If they decide it’s time to give the impression the economy is in deep trouble—and therefore the economic policies of a president sitting in the White House are disastrous for the country—they take the stock market down.

Every president faces this situation. He’s at the mercy of forces beyond his control—unless he tries to expose the game and show the American people what’s really going on.

But most presidents are unaware of the overall op. If they do know the score, they’re reluctant to blow the whistle on it, in part because they believe the public is too ignorant to grasp the mechanics of how the op works. And the howling press, firmly in the pocket of the insiders, would call the president a conspiracy nutcase in a hundred different ways, day and night, 24/7.

The stock market is a casino. The economy is the economy. They are two separate realities.

But shills and operatives and propagandists and sold-out economists and idiot financial reporters forever connect the two realities and make it seem as if they are entangled in an intimate cause-and-effect relationship.

They aren’t.

Many people believe the sale of stock benefits a company. This is true when a privately held company goes public by issuing stock in what’s called an initial public offering (IPO). During the limited time period of the IPO, money from the sale of stock does go back to the company issuing it, and that money can used for company growth. Yes.

Later, the company can issue more stock in what’s called a follow-on offering, and then, too, money from the sale of the stock goes back to the company.

But…by far the greatest amount of activity in the stock market is the simple buying and selling of shares…and none of the ensuing profits and losses accrue to the companies whose shares are being traded. It’s a pure casino operation.

This casino operation does nothing to benefit the companies in the way of adding cash to their assets.

Consider what can happen to a large retirement pension fund. The fund takes in money from employees. It will later pay back that money, plus “add-ons.” How? The pension fund invests a great deal of the money it is holding in the stock market. It buys a variety of stocks and sells them and buys them and sells them. So if those stocks plummet and stay down, and the pension fund isn’t willing to ride out the storm in hopes that the fall will eventually turn into a rise, the pension fund will sell off those stocks and end up losing much money. It gambled in the casino with other people’s money, and it lost.

But even here, the reason for the loss was an incorrect perception/prediction about what was going to happen in the casino. It wasn’t about actualities of the economy.

Getting the picture?

Fake reality.

Top to bottom.


The Matrix Revealed

(To read about Jon’s mega-collection, The Matrix Revealed, click here.)


Jon Rappoport

The author of three explosive collections, THE MATRIX REVEALED, EXIT FROM THE MATRIX, and POWER OUTSIDE THE MATRIX, Jon was a candidate for a US Congressional seat in the 29th District of California. He maintains a consulting practice for private clients, the purpose of which is the expansion of personal creative power. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world. You can sign up for his free NoMoreFakeNews emails here or his free OutsideTheRealityMachine emails here.

My prediction about Facebook came true

My prediction about Facebook came true

by Jon Rappoport

August 19, 2014

www.nomorefakenews.com

Two years ago, I wrote about the origins of Facebook. The company had gone public with its IPO, which was tanking badly.

Here are key excerpts from the article:

“But now the Facebook stock has tanked. On Friday, August 17, [2012] it weighed in at half its initial IPO price. For the first time since the IPO, venture-capital backers were legally permitted to sell off their shares, and some did, at a loss.”

“This has the earmarks of a classic shakeout and squeeze play…First, they [insiders] drive down the price of the stock, then they trade it at low levels that discourage and demoralize the public and even semi-insiders. As the stock continues to tank, they quietly buy up as much of it as they can. Finally, when the price hits a designated rock bottom, they shoot it up all the way to new highs and win big.”

*** “The company is too important as a data-mining asset of the intelligence community to let it fall into disrepair and chaos.”

“The media will play along, pretending the eventual upswing-recovery of Facebook stock happens for fundamental reasons connected to the company’s ‘better level of performance’. The media take this approach to every stock and every company, to avoid letting the public know how massive manipulation actually runs these trading markets.”

Okay. So let’s look at what’s happened to Facebook stock since I wrote those words two years ago.

From August 2012 all the way to July 2013, the stock presented a quite discouraging picture. It stayed in the 20-30 range, looked like it was going nowhere, and never threatened to move up to its original offering price of 40.

Exactly. This prompted many holders to dump their shares, affording insiders the opportunity to scoop them up at bargain-basement prices.

Finally, in July 2013, the insiders began the long march upward, which has continued to this day. As I write this, Facebook stock is selling at $75.39 a share, a new high.

Perfect.


power outside the matrix


Analysts, of course, attribute this boom to company “earnings beating projections.”

They always find a reason. They’ll say anything. “The weather last year was unusually cold.”

The fact is, Facebook was in good hands all the way. The heavy hitters took the price way down, kept it there, accumulated many, many shares, and then marched the price up to the sky.

In Facebook, the CIA and other intelligence agencies have had a great front for their data-mining work, and they weren’t going to let it fail.

As for the future, the insiders could take FB shares down again, let them languish, and then rocket them up. Why make just one big score when you can double-dip and make two?

Jon Rappoport

The author of three explosive collections, THE MATRIX REVEALED, EXIT FROM THE MATRIX, and POWER OUTSIDE THE MATRIX, Jon was a candidate for a US Congressional seat in the 29th District of California. He maintains a consulting practice for private clients, the purpose of which is the expansion of personal creative power. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world. You can sign up for his free emails at www.nomorefakenews.com

Facebook, the CIA, DARPA, and the tanking IPO

Facebook, the CIA, DARPA, and the tanking IPO

By Jon Rappoport

August 20, 2012

NoMoreFakeNews.com

The big infusion of cash that sent Mark Zuckerberg and his fledgling college enterprise on their way came from Accel Partners, in 2004.

Jim Breyer, head of Accel, attached a $13 million rocket to Facebook, and nothing has ever been the same.

Earlier that same year, a man named Gilman Louie joined the board of the National Venture Capital Association of America (NVCA). The chairman of NVCA? Jim Breyer. Gilman Louie happened to be the first CEO of the important CIA start-up, In-Q-Tel.

In-Q-Tel was founded in 1999, with the express purpose of funding companies that could develop technology the CIA would use to “gather data.”

That’s not the only connection between Jim Breyer and the CIA’s man, Gilman Louie. In 2004, Louie went to work for BBN Technologies, headed up by Breyer. Dr. Anita Jones also joined BBN at that time. Jones had worked for In-Q-Tel and was an adviser to DARPA, the Pentagon’s technology department that helped develop the Internet.

With these CIA/Darpa connections, it’s no surprise that Jim Breyer’s jackpot investment in Facebook is not part of the popular mythology of Mark Zuckerberg. Better to omit it. Who could fail to realize that Facebook, with its endless stream of personal data, and its tracking capability, is an ideal CIA asset?

But now the Facebook stock has tanked. On Friday, August 17, it weighed in at half its initial IPO price. For the first time since the IPO, venture-capital backers were legally permitted to sell off their shares, and some did, at a loss.

Articles have begun appearing that question Zuckerberg’s ability to manage his company. “Experts” are saying he should import a professional team to run the business side of things and step away.

All this, despite the fact that Facebook’s first posted revenue as a public company has exceeded analysts’ predictions, according to the LA Times.

This has the earmarks of classic shakeout and squeeze play. It’s how heavy hitters gain control of a company. First, they drive down the price of the stock, then they trade it at low levels that discourage and demoralize the public and even semi-insiders. As the stock continues to tank, they quietly buy up as much of it as they can. Finally, when the price hits a designated rock bottom, they shoot it up all the way to new highs and win big.

And they hold enough shares to exert more control over the company itself.

That is how Facebook will survive. Zuckerberg’s grip on Facebook will loosen.

The company is too important as a data-mining asset of the intelligence community to let it fall into disrepair and chaos. The CIA and its cutouts will save it and gain more power over it. It’s what they’ve wanted all along.

From the time Mark Zuckerberg was a child and attended the summer camp for “exceptional children,” CTY (Center for Talented Youth), run by Johns Hopkins University, he, like other CTY students, Sergey Brin (co-founder of Google), and Lady Gaga, have been easy to track.

CTY and similar camps filter applications and pick the best and brightest for their accelerated learning programs. Tracing the later progress of these children in school and life would be a standard operation for agencies like the CIA.

When Zuckerberg founded an interesting little social network at Harvard, and then sought to turn it into a business, the data-mining possibilities were obvious to CIA personnel. Through their cutouts, as described above, they stepped in and lent a helping hand.


The Matrix Revealed


Now it’s time for Zuckerberg to pass the baton to his handlers, so they can maximize the economics of Facebook and utilize it to spy even more extensively.

The media will play along, pretending the eventual upswing-recovery of Facebook stock happens for fundamental reasons connected to the company’s “better level of performance.” The media take this approach to every stock and every company, to avoid letting the public know how massive manipulation actually runs these trading markets.

Sources:

http://www.crunchbase.com/person/jim-breyer

http://www.investigatemagazine.co.nz/Investigate/?p=1601

Jon Rappoport

The author of three explosive collections, THE MATRIX REVEALED, EXIT FROM THE MATRIX, and POWER OUTSIDE THE MATRIX, Jon was a candidate for a US Congressional seat in the 29th District of California. He maintains a consulting practice for private clients, the purpose of which is the expansion of personal creative power. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world. You can sign up for his free NoMoreFakeNews emails here or his OutsideTheRealityMachine emails here.

Leveraging Global Warming

Leveraging Global Warming

by Jon Rappoport

December 30, 2009 

I’m offering an experimental hypothesis here, based on how markets work.  I’m talking about trading markets—stocks, commodities.

As you know, the (false) science of climate change is a lever for a new type of market; trading “permits” or “offsets” in carbon.

First a permitted ceiling for the total burning of carbon is set.  Then, people and companies can trade the right to burn it.  Those who burn a great deal can buy permits from those who burn a little, and of course, millions of investors can speculate, as they do in other markets.

However, there is another benefit for investors—as long as the market in carbon lasts.  Holding permits can function as collateral in leveraging loans.

Right now, if I hold stock in corporations, I can use it to borrow money.  It’s the same with carbon permits.

In these times, when loans can be hard to come by, any collateral is good and useful, even if it is based on the most preposterous science.

I believe that is a hidden factor behind the initiating of this carbon-trading scheme.  Private companies, individuals, and most definitely, governments want the juice to float huge loans.

Right now, the US government is borrowing from itself in various ways to pump up the impression that it is solvent.  This scam extends to the Fed, which appears to be part of the government but really isn’t.

The US government is desperately looking for “legitimate” collateral.  Therefore, we can expect, if climate legislation capping carbon emissions passes through Congress, the federal and state governments will jump hard into the carbon-trading markets.  And THEN, they will use their market position to float loans.

Yes, it’s musical chairs, and it’s bubble making, and the crash would be as severe as what happened in the housing-mortgage market, but the government doesn’t care.  Their sand castles are crumbling in the waves, and they’re doing whatever they can, right now, to shore them up.

“Oh, you’re flush in the carbon market?  Wow, that’s very hip and very now. Everybody wants to reduce global warming.  What?  You want to borrow money against your emission permits?  Sure, we can do that for you.  Terrific.”

Yes, terrific, for a little while.

One might say the whole global warming scam was projected, so that a carbon market would emerge AND become a source for obtaining loans.  Because, after all, the credit game (the loan game) is the biggest money game in the world, and has been for some time.


The Matrix Revealed

(To read about Jon’s mega-collection, The Matrix Revealed, click here.)


Jon Rappoport

The author of three explosive collections, THE MATRIX REVEALED, EXIT FROM THE MATRIX, and POWER OUTSIDE THE MATRIX, Jon was a candidate for a US Congressional seat in the 29th District of California. He maintains a consulting practice for private clients, the purpose of which is the expansion of personal creative power. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world. You can sign up for his free NoMoreFakeNews emails here or his free OutsideTheRealityMachine emails here.

Explosive Conflict of Interest: Who Profits from the National Health Plan?

Explosive Conflict of Interest: Who Profits from the National Health Plan?

And from Other Investments…

by Jon Rappoport

December 24, 2009 

I have to begin by saying you need to know about Walter Burien.  CAFR1.com

Walter curls people’s hair.  For many years, he has been investigating the investments made by governments.  The what?  I know.  This sounds like a non-sequitur.  Governments aren’t businesses, are they?

It turns out they are.  Well, when you think about it, it’s obvious.  They run, for example, retirement funds for their employees, and those funds make investments, they don’t just store money in shoe boxes.

 Recently, Walter provided a link to the New York State Retirement Fund Asset Listing (March 31, 2006).  You can find it at: http://cafr1.com/STATES/NEWYORK/RETIREMENT/NYRINV2006.PDF

This document shows the investments this fund makes, and the value of each stock holding.  The implications are enormous.  For example, when you pinpoint the many pharmaceutical stocks, you realize New York State government will be a primary beneficiary of any national health plan.  Why?  Because drug companies, under such a plan, will be selling far more drugs as millions of new, previously uninsured people come under the federal umbrella.

Any piece of news that makes the pharma landscape glow tends to shoot up stock values.

From a financial point of view, it would be ridiculous to assume New York State government would oppose national health insurance.  It’s good for business.  The business of, yes, New York State government.

And by the way, to the extent that some of these drug companies manufacture vaccines (and they do), the New York State government would be a big-time supporter of the mass vaccinations that accompany each new phony epidemic, such as Swine Flu.  Again, for business reasons.  In fact, we may now understand a new reason why, until huge protests derailed it, New York tried to make the H1N1 vaccine mandatory for all state health workers.    

Here are some of the pharmaceutical listings in the New York Retirement Fund.  The value of each stock holding is as of Mar.31, 2006.

Schering-Plough: $138,013,129

Barr: $39,152, 525

Baxter: $105,606, 745

Gilead: $127,348,101

Roche: $87,762,875

MedImmune: $46,942, 968

Sanofi-Aventis:$153,887,891

Bayer: $39,318,918

Bristol-Myers Squibb: $195,807,422

GlaxoSmithKline: $137,729,350

Pfizer: $834,756,329

Novartis: $131,221,033

Merck: $344,768,742

Eli Lilly: $249,409,636

Vertex: $17,947,395

Drug companies.  $2.5 billion and change.  One retirement fund in one state.

Walter Burien goes much further—and here you would have to consult his site for supporting evidence.  He states that, when you look at the various investment funds of the 50 state governments, and when you consider the possibility that many of these funds act (invest) in concert, governments turn out to be controlling stockholders in some of the biggest corporations in America.

Turn that thought over in your mind a few times.

Here’s another explosion:  To what degree did the federal bailout bail out the New York State government?  Well, among the 2006 NY Retirement Fund listings, we have:

Goldman Sachs: $268,770,613

Bank of America: $896,993,638

Citigroup: $1,036,682,080.

This gives another perspective on what a fed bailout means.  It functions as profit protection.  For a state government.

Imagine state legislators and other state officials consulting THE INVESTMENT PORTFOLIO of their state government before they vote for or against legislation. 

The hits keep coming.

“As governor of your state, my friends, I am taking every action I can to assure the profits of this administration continue to rise.  As taxpayers, you are the stakeholders.  What you pay us, we invest.  Of course, we never show you the balance sheet, and we never indicate whether we need your taxes, or whether our profits alone are sufficient for running the state.  But that’s the way the game works.  You stay in the dark.  When we raise your taxes, we give you reasons—which may be accurate or sheer nonsense.  The point is, we keep taking your money and investing it…” 


The Matrix Revealed

(To read about Jon’s mega-collection, The Matrix Revealed, click here.)


Jon Rappoport

The author of three explosive collections, THE MATRIX REVEALED, EXIT FROM THE MATRIX, and POWER OUTSIDE THE MATRIX, Jon was a candidate for a US Congressional seat in the 29th District of California. He maintains a consulting practice for private clients, the purpose of which is the expansion of personal creative power. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world. You can sign up for his free NoMoreFakeNews emails here or his free OutsideTheRealityMachine emails here.